CND Life Sciences
United States
- Scottsdale, Arizona
- 07/04/2023
- Seed
- $4,500,000
CND Life Sciences is dedicated to supporting the care of patients suffering from neurodegenerative diseases and other conditions. Operating a CLIA-certified laboratory in Scottsdale, AZ, CND launched the Syn-One Test® as the first commercially available test to detect, visualize, and quantify the presence of misfolded phosphorylated alpha-synuclein in cutaneous nerve fibers. The test serves as an objective diagnostic tool to aid in the confirmation of a synucleinopathy in patients with suspected Parkinson’s disease (PD), dementia with Lewy bodies (DLB), multiple system atrophy (MSA), or pure autonomic failure (PAF). Through analysis of three small in-office skin biopsies provided by a referring physician, CND offers a convenient, accurate, minimally invasive alternative to aid in the diagnosis of neurodegenerative diseases. The company has research collaborations with multiple biopharmaceutical companies and is committed to advancing science in the field.
- Industry Medical and Diagnostic Laboratories
- Website https://cndlifesciences.com/
- LinkedIn https://www.linkedin.com/company/cnd-life-sciences/
Forage | $40,000,000 | (Jun 5, 2026)
InCharge Energy | $46,000,000 | (Jun 5, 2026)
Oak Hill Bio | $32,500,000 | (Jun 5, 2026)
ZutaCore | $100,000,000 | (Jun 5, 2026)
Terra AI | $20,000,000 | (Jun 5, 2026)
Town | $55,000,000 | (Jun 5, 2026)
Lassie | $35,000,000 | (Jun 5, 2026)
OFFROAD | $7,000,000 | (Jun 5, 2026)
Shifters | $10,200,000 | (Jun 5, 2026)
Quobly | $133,545,475 | (Jun 5, 2026)
Scispot | $8,000,000 | (Jun 5, 2026)
Scotch | $20,000,000 | (Jun 5, 2026)